Next Article in Journal
Improved Biohythane Production from Rice Straw in an Integrated Anaerobic Bioreactor under Thermophilic Conditions
Next Article in Special Issue
Clinical Utility of the FilmArray® Blood Culture Identification (BCID) Panel for the Diagnosis of Neonatal Sepsis
Previous Article in Journal
Gut Microbiota and Metabolome Changes in Three Pulmonary Hypertension Rat Models
Previous Article in Special Issue
Early Diagnosis of Late-Onset Neonatal Sepsis Using a Sepsis Prediction Score
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Microorganisms
Volume 11
Issue 2
10.3390/microorganisms11020473
microorganisms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Antimicrobial Exposure in Critically Ill Patients with Sepsis-Associated Multi-Organ Dysfunction Requiring Extracorporeal Organ Support: A Narrative Review

by
Salvatore Lucio Cutuli
1,2,*,
Laura Cascarano
1,2,
Paolo Lazzaro
1,2,
Eloisa Sofia Tanzarella
1,2,
Gabriele Pintaudi
1,2,
Domenico Luca Grieco
1,2,
Gennaro De Pascale
1,2 and
Massimo Antonelli
1,2
1
Dipartimento di Scienze dell’Emergenza, Anestesiologiche e Della Rianimazione, Fondazione Policlinico Universitario A. Gemelli IRCCS, L.go A. Gemelli 8, 00168 Rome, Italy
2
Dipartimento di Scienze Biotecnologiche di Base Cliniche Intensivologiche e Perioperatorie, Universita’ Cattolica del Sacro Cuore, Rome, L.go F. Vito 1, 00168 Rome, Italy
*
Author to whom correspondence should be addressed.
Microorganisms 2023, 11(2), 473; https://doi.org/10.3390/microorganisms11020473
Submission received: 6 January 2023 / Revised: 6 February 2023 / Accepted: 12 February 2023 / Published: 13 February 2023
(This article belongs to the Special Issue Advances in Bacterial Sepsis)
Browse Figure
Review Reports Versions Notes

Abstract

:
Sepsis is a leading cause of disability and mortality worldwide. The pathophysiology of sepsis relies on the maladaptive host response to pathogens that fosters unbalanced organ crosstalk and induces multi-organ dysfunction, whose severity was directly associated with mortality. In septic patients, etiologic interventions aiming to reduce the pathogen load via appropriate antimicrobial therapy and the effective control of the source infection were demonstrated to improve clinical outcomes. Nonetheless, extracorporeal organ support represents a complementary intervention that may play a role in mitigating life-threatening complications caused by sepsis-associated multi-organ dysfunction. In this setting, an increasing amount of research raised concerns about the risk of suboptimal antimicrobial exposure in critically ill patients with sepsis, which may be worsened by the concomitant delivery of extracorporeal organ support. Accordingly, several strategies have been implemented to overcome this issue. In this narrative review, we discussed the pharmacokinetic features of antimicrobials and mechanisms that may favor drug removal during renal replacement therapy, coupled plasma filtration and absorption, therapeutic plasma exchange, hemoperfusion, extracorporeal CO2 removal and extracorporeal membrane oxygenation. We also provided an overview of evidence-based strategies that may help the physician to safely prescribe effective antimicrobial doses in critically ill patients with sepsis-associated multi-organ dysfunction who receive extracorporeal organ support.

1. Introduction

Sepsis is a heterogenous clinical syndrome characterized by host and pathogen factors [1] and represents a major cause of disability and mortality worldwide [2]. Sepsis originates from a maladaptive response to infection leading to unbalanced organ crosstalk and multi-organ dysfunction (MOD), whose severity was directly associated with clinical complications and mortality [1]. The burden of sepsis may be mitigated by etiologic interventions that aim to reduce the pathogen load via therapeutic exposure [3] to appropriate antimicrobials (that is the antimicrobial-free fraction concentration matching pathogen susceptibility) [4] and effective control of source infection [5]. However, “standard” dosing regimens based on empiric rules in critically ill septic patients were associated with inadequate antimicrobial exposure, which was mostly due to sepsis-associated homeostatic alterations affecting the drug distribution and clearance [3,6,7], and implied an increased risk of worse clinical outcomes [3].
Moreover, inadequate antimicrobial exposure may be fostered by the concomitant delivery of extracorporeal organ support (ECOS) [8,9], which includes several blood purification therapies widely used in clinical practice to mitigate the life-threatening complications of MOD (e.g., hyperuremia, fluid overload and acid base imbalances) [10,11]. In this setting, several studies raised concern about the suboptimal antimicrobial exposure associated with ECOS [12] leading to enhanced risk of treatment failure and the emergence of multi-drug resistant (MDR) pathogens [13,14]. For these reasons, the 2021 Surviving Sepsis Campaign (SSC) guidelines recommended administering empiric antimicrobials immediately after sepsis recognition and optimizing dosing strategies based on pharmacokinetic/pharmacodynamic (PK/PD) principles, with the aim of maximizing pathogen killing and preventing drug toxicity [15]. In the light of this view, several antimicrobial dosing strategies have been proposed and include unit-level interventions (e.g., prolonged infusion), nomograms or therapeutic drug monitoring (TDM) [6,16,17].
In this narrative review, we highlighted the PK alterations of antimicrobials induced by sepsis and ECOS. Moreover, we focused on specific antimicrobial properties that may favor drug removal via ECOS. Finally, we provided an overview of strategies that may help the clinician to overcome the issue of inadequate antimicrobial exposure during ECOS in critically ill patients with sepsis-associated MOD.

2. PK/PD Considerations

Antimicrobial therapy is one of the most common pharmacologic interventions prescribed in the ICU [18,19]. In order to maximize pathogen-killing and avert drug toxicity, antimicrobial dosing strategies should be oriented by a personalized approach based on PK/PD principles [16,20] and not standardized on empiric rules neglecting patient demographic and clinical characteristics, pathogen features and antimicrobial properties (Figure 1).
The PK profile of an antimicrobial relies on the interaction between patient characteristics (e.g., body composition or organ function), concurrent interventions (e.g., ECOS) and drug properties (physiochemical features and clearance, Table 1) affecting the time-course concentration of the antimicrobial in specific tissues [21]. In contrast, the PD profile refers to the antimicrobial mechanism of action (Figure 1). According to PK/PD principles, an effective antimicrobial dose should deliver an adequate antimicrobial-free fraction concentration at the source of infection, in order to match pathogen susceptibility expressed using the minimum inhibitory concentration (MIC) [22]. The MIC is determined in vitro and represents the antimicrobial concentration (twofold dilutions up and down starting from 1 mg/L) that prevents visible growth over 18 + 2 h at 34–37 °C, using a standardized inoculum, thus representing the bacteriostatic/bactericidal effect of the drug over time [23]. However, the MIC measurement is burdened by biological (strain-to-strain differences) and laboratory (e.g., assay used, inoculum preparation, incubation temperature and time, technical skills) variations [23]. In order to overcome the heterogeneous assessment of MIC among different laboratories, the breakpoints for phenotypic pathogen susceptibility to antimicrobials are determined by regulatory agencies such as the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [24] that revise and publish updated tables yearly based on a complex scientific process that accounts for: the target infection, drug (e.g., dosage, mode of administration, PK and PD) and pathogen (e.g., resistance mechanisms) characteristics, disk diffusion methods and zone diameter distributions, epidemiological cut-off values, MIC distributions and clinical outcomes. The EUCAST antimicrobial susceptibility testing breakpoints are reported as MIC breakpoint values (mg/dl) and zone diameter breakpoint values (mm), and graded as:
−
S—susceptible, standard dosing regimen: high likelihood of therapeutic success using a standard dosing regimen of the antimicrobial;
−
I—susceptible, increased exposure: high likelihood of therapeutic success if antimicrobial exposure is improved by increasing the dosing regimen in order to reach high drug concentration at the site of infection;
−
R—resistant: high likelihood of therapeutic failure even for increased exposure.
Consequently, higher antimicrobial exposure is required for the treatment of less susceptible strains and, whenever the measured MIC of a pathogen causing a specific infection (e.g., pneumonia, bacteremia, meningitis, etc) is above the MIC breakpoint indicating antimicrobial resistance, some author suggested to target an antimicrobial exposure at the source of infection equal to 4 x pathogen MIC, unless the drug dose exceeds the threshold of toxicity [25].

2.1. PK Alterations Induced by Sepsis

Antimicrobials are characterized by specific properties, whose interaction with sepsis-induced MOD influence their distribution and time-course concentration in different tissues:
➢
Solubility is the major determinant of antimicrobial volume of distribution (Vd), which is the theoretical volume necessary to contain the total amount of the drug at the same concentration measured at the steady state in the plasma. The Vd drives the titration of the loading dose of antimicrobials [26].
Specifically, hydrophilic antimicrobials (e.g., ß-lactams, aminoglicosides, glycopeptides, daptomycin and polymyxins) are characterized by small Vd (<2 L/kg), being mainly concentrated into the bloodstream. However, sepsis-associated endothelial dysfunction and capillary leak syndrome coupled with fluid overload due to large fluid resuscitation and oliguric acute kidney injury (AKI), may lead to extravascular fluid shift and, consequently, low bloodstream concentration of hydrophilic antimicrobials. This condition implies an increase in the loading dose in order to secure an effective exposure to these drugs. In contrast, lipophilic antimicrobials (e.g., fluoroquinolones, glycocyclines, lincosamides, macrolides) are characterized by large Vd (>2 L/kg) and are not significantly influenced by fluid shift, being mainly concentrated in the adipose tissue.
➢
Protein binding varies among antimicrobials (Table 1). The main carriers of antimicrobials into the bloodstream are represented by albumin for acidic drugs (e.g., aminoglycosides and levofloxacin) and α1-acid glycoprotein for basic drugs [21], in accordance with to the Gibbs–Donnan effect.
➢
In critically ill patients, hypoalbuminemia has been frequently reported [27], and this condition may alter the PK profile of highly-protein bound antimicrobials (e.g., ß-lactams, glycopeptides, glycylcyclines, lincosamides, daptomycin and macrolides), leading to augmented free fraction, Vd and clearance.
➢
Electrostatic interactions regulate the degree of antimicrobial ionization and free fraction, the amount of which relies on the pKa of the drug. Specifically, the free fraction of weak basis-like antimicrobials is increased by pH of tissues below pKa, while the dissociation of weak acid-like antimicrobials is favored by local pH above the pKa [21].
➢
Molecular size influences drug excretion. Small molecules are preferentially filtered by the kidney into urine and large molecules are secreted by the liver into the bile [21].
➢
Clearance refers to the volume of plasma purified from antimicrobials per unit of time and drives the titration of the maintenance dose [26]. Catabolism and excretion of hydrophilic antimicrobials take place predominantly in the kidney (e.g., ß-lactams, aminoglucosides, glycopeptides, daptomycin, oxazolidones, polymyxins), while the liver plays a role of paramount importance for lipophilic antimicrobials (e.g., glycylcyclines and macrolides). Sepsis-associated MOD may induce alterations of antimicrobial metabolism [21] leading to suboptimal exposure or intoxication. In the early phases of sepsis, hyperdynamic states due to cardiac output increase may enhance glomerular filtration rate, leading to augmented renal clearance [6,14] and suboptimal antimicrobial exposure when prescribed at standard dosing regimens. On the contrary, sepsis is the major cause of AKI [28], and this condition may increase the risk of antimicrobial accumulation and toxicity.

2.2. PK Alterations Induced by ECOS

ECOS represents an additional PK compartment that may influence antimicrobial exposure by altering the distribution and clearance of these drugs. The delivery of ECOS implies an unavoidable administration of intravascular volume due to priming solution, which increases Vd and lowers the bloodstream concentration of hydrophilic drugs [20]. Moreover, antimicrobials may be cleared via ECOS (Table 2) through absorption or trans-membrane removal (Table 2). Absorption is influenced by the biochemical interaction of the drug with the internal surface of the device, and represents the main mechanism of antimicrobial removal during hemoperfusion, coupled plasma filtration and absorption (CPFA), extracorporeal CO2 removal (ECCO2-R) and extracorporeal membrane oxygenation (ECMO). Trans-membrane removal is regulated by concentration gradients (haemodialysis, HD), pressure gradients (hemofiltration, HF) or both (hemodiafiltration, HDF) along the device [10,11]. Trans-membrane removal relies on the interaction between the physiochemical properties of the drug (e.g., solubility and protein binding) and the membrane (e.g., material and permeability), the technique (e.g., HD, HF, HDF) and its setting (e.g., dose). This is the leading mechanism of antimicrobial removal during renal replacement therapy (RRT), CPFA and therapeutic plasma exchange (TPE).

3. Potential Pitfalls in the Evaluation of ECOS-Related Antimicrobial PK Alterations

The majority of research on PK alteration of antimicrobials induced via ECOS is represented by small case series not accounting for the endogenous clearance (residual kidney and liver function) [36], thus implying low external validation and reproducibility. In this context, a potentially useful method to assess residual renal function in severe critically ill patients may be represented by the measurement of the 2-h creatinine clearance [37].
Moreover, most of the studies in this field are represented by pre-clinical investigations using mechanistic ex vivo one-compartment models, whose translation into the clinical scenario may be limited by several factors. First, ex vivo models do not account for the endogenous clearance of antimicrobials. Second, antimicrobials are dissolved in surrogate solutions of patient’s blood (e.g., crystalloids, albumin or plasma) that may alter the PK characteristics of the drug (e.g., solubility and free fraction). Third, ex vivo models evaluate the effect of ECOS on a single antimicrobial dose, thus underestimating drug accumulation and device saturation for repeated antimicrobial administration, both mitigating the impact of ECOS on antimicrobial exposure in vivo. For these reasons, in our review, we preferentially reported the results of clinical studies over ex vivo models and mentioned the latter if we could not retrieve evidence in vivo.

4. Renal Replacement Therapy

Sepsis is the major cause of AKI in the ICU [28]. Specifically, the 15% of critically ill patients with septic AKI require RRT [38], and these patients are burdened by 50% higher mortality than patients on RRT without septic AKI [39]. The SMARRT trial [40] was a large multicenter study (29 ICUs from 14 countries) that investigated antimicrobials’ PK (piperacillin, tazobactam, meropenem and vancomycin) during CRRT, and reported a considerable variation of RRT modes and intensities, total estimated renal clearance (defined as total RRT effluent rate and patient’s intrinsic glomerular filtration rate) and antibiotic dosing among the 381 critically ill patients included. Moreover, this study revealed that a “standard” dosing regimen failed to achieve the target antimicrobial exposure in ≥25% of patients and was associated with increased mortality. Accordingly, the SMARRT trial [40] demonstrated that ensuring target antimicrobial exposure by the use of empirical dosing regimens is challenging and implied drug dosing adjustment in response to the real time measurement of antimicrobials. In critical care practice, most of the recommendations on antimicrobial dosing are outdated in comparison with the advancing RRT technology, or are extrapolated from reports in non-critically ill patients with stable chronic kidney disease on intermittent RRT [29]. In this setting, the extracorporeal clearance of an antimicrobial is commonly considered significant when it is higher than the 25% of the total body clearance [26]. In this review we focused on CRRT, which is the most common RRT modality used in European and Australian ICUs, although its use has been increasing in the United States [41]. Specifically, we discussed antimicrobial characteristics that may enhance drug removal during CRRT and provided scientific evidence of this phenomenon.

4.1. Membrane Characteristics

The material and internal surface area of CRRT membranes may influence the amount of antimicrobial removal via absorption, which is greater for polyacrylonitrile compared with polysulfone or polymethylmetacrylate membranes (e.g., for gentamycin and tigecycline [42]). Moreover, Ulldemolins et al. [43] reported that larger doses of piperacillin-tazobactam were required to achieve adequate bloodstream concentration for acrylonitrile 69 surface-treated (AN69ST internal surface: 1.5 m2) membranes compared with the AN69 (internal surface: 0.9 m2). However, limited evidence exists on the clinical impact of this phenomenon, especially for newly developed membranes (e.g., the AN69ST [44]).
Membrane permeability to solutes is expressed by the Sieving coefficient (SC) for hemofiltration and the saturation coefficient (SA) for hemodialysis, which is about 30–40% less than SC. The SC refers to the ratio of solute concentration in the ultrafiltrate to solute concentration in the bloodstream, while the SA corresponds to the ratio of solute concentration in the dialysate to solute concentration in the bloodstream [45]. Accordingly, trans-membrane solute removal is negligible for SC or SA equal to 0 and is maximal for SC or SA equal to 1. These coefficients are dynamic and decrease proportionally to the duration of each treatment session and the filtration fraction (effluent flow rate/plasma flow rate) [46], due to progressive clotting and the stratification of protein cake on the internal surface of the membrane [11]. Moreover, trans-membrane antimicrobial removal with low-flux membranes (ultrafiltration coefficient, KUF < 12 mL/mmHg/h) is negligible for molecular weight >1000 Da, while it is relevant with high-flux membranes (KUF >12 mL/mmHg/h, mean pore radius 3.9 nm, cutoff around 20–30 KDa) and may be even greater for medium (mean pore radius 5 nm) and high-cutoff (mean pore radius 10 nm, cutoff above 60 KDa) membranes.

4.2. Setting

Hydrophilic drugs with small molecular weight (<500–1000 Da), low protein binding (<80%) and small Vd (<2 L/Kg) are theoretically susceptible to trans-membrane removal during HD [29,30]. In contrast, drugs with larger molecular weight could be efficiently removed via HF or HDF. The SMARRT trial [40] reported a large variability of tazobactam and vancomycin bloodstream concentrations in relation to the type of CRRT, with a higher rate of removal for CVVHF and CVVHDF than for CVVHD.
The effluent flow rate (intensity) refers to the volume of blood cleared from solute by the extracorporeal circuit per unit of time and body weight (mL/kg/h) [10,11]. The optimal dose of CRRT in critically ill septic patients with AKI has been debated over the last decades and post hoc analyses of large randomized clinical trials revealed significant variability of antimicrobial concentration during CRRT, possibly due to the adoption of different empiric dosing strategies and CRRT intensities among participating centers [47]. For this reason, no specific “standard” antimicrobial dosing strategy may be recommended to match all forms and prescriptions of RRT. In 2014, Jamal et al. [48] conducted a systematic review and meta-analysis to investigate the PK alterations associated with the different RRT modalities and settings of antipseudomonal β-lactams (such as meropenem and piperacillin) and vancomycin. This study included 30 original articles (349 patients) and found a direct correlation between the CRRT dose and extracorporeal elimination of these drugs. In contrast, a post hoc pharmacokinetic analysis of the RENAL trial [49] failed to demonstrate a dose-dependent relationship of antimicrobial removal (ciprofloxacin, meropenem, piperacillin, tazobactam and vancomycin) between 40 mL/kg/h and 25 mL/kg/h). Nonetheless, the IVOIRE study [50] found that a higher CRRT intensity (70 mL/kg/h) significantly shortened antimicrobial half-lives compared with a lower CRRT intensity (35 mL/kg/h), although antimicrobials were not specified and residual renal function was not assessed.
Recently, Backdach et al. [51] systematically reviewed the results of 27 articles on PK/PD characteristics of novel β-lactams and β-lactams/β-lactamase inhibitors in critically ill patients receiving ECOS. Specifically, they found that increasing doses of Cefiderocol (standard dose: 2 g Q8h) might be necessary to attain PK/PD indexes in relationship with residual renal function, highly resistant pathogen and CRRT intensity (from 1.5 g Q12h for effluent flow rate ≤ 2 L/h to 2 g Q8h for effluent flow rate ≥ 4 L/h), while the maintenance dose of Ceftolozane/Tazobactam should be lowered (from 1.5–3 g Q8h to 0.75 Q8h) during CRRT. In contrast, no evidence was available for other antimicrobials such as Caftazidime/Avibactam, Imipenem/Relabatam and Meropenem/Vaborbactam [51].

4.3. Central Venous Catheters Tip Location

The Kidney Disease Improving Global Outcome (KDIGO) guidelines [52] recommended to place the central venous dialysis catheter in the superior cava vein district as preferential choices: right jugular vein (first choice), femoral vein (second choice), left jugular vein (third choice) and subclavian vein (last choice). However, some experimental and pre-clinical studies demonstrated the influence of the distance between the central venous catheter (used for drug infusion, central venous pressure monitoring or blood withdrawal) and the central venous dialysis catheter on drug removal. Specifically, they found that drug aspiration was minimal when the central venous catheter tip was placed 0–2 cm distally to the central venous dialysis catheter tip and drug aspiration was maximal when withdrawing the former proximately to the latter at a distance of 4 cm [53,54]. Moreover, the drug infusion speed may affect the amount of drug aspiration much more than the RRT blood flow rate [53]. In contrast, an animal model demonstrated that bloodstream concentrations of drugs (noradrenaline and gentamycin) were less affected via RRT when the central venous catheter and central venous dialysis catheter tips were placed in different central venous districts (e.g., internal jugular vein and femoral vein) [55]. However, no research has assessed the impact of catheter tip location on antimicrobial removal in a clinical setting.

5. Therapeutic Plasma Exchange

TPE allows patient’s plasma removal and replacement with human donor plasma, colloids, crystalloids or a mixture thereof, with the aim to improve immune dysfunction and coagulation abnormalities [31]. TPE is mainly used for specific clinical conditions (e.g., myasthenia gravis, Guillain–Barré syndrome and Waldenström macroglobulinemia) [31], although recent studies reported some hemodynamic improvement associated with this therapy in septic patients [56,57]. Low Vd and high protein binding (>80%) may enhance antimicrobial removal during TPE, while molecular size has no role in this setting [31]. Moreover, antimicrobial removal may be increased by the replacement of large plasma volume and drug administration immediately before the TPE session [31]. Recently, Krzych et al. [58] reviewed the current literature and found that ß-lactams (cefazolin and ceftriaxone) and liposomal Amphotericin B are significantly removed via TPE. However, such evidence came from pre-clinical models or small case series, thus warranting future clinical investigation.

6. Coupled Plasma Filtration and Absorption

The CPFA combines plasma filtration and adsorption via styrene resin. Briefly, the volume of plasma purified via mediators is reinfused into the blood line, which passes across an hemofilter [44].
CPFA was demonstrated to significantly lower the bloodstream concentration of colistin, whose amount was directly proportional to the volume of plasma filtered over time [32]. Moreover, a retrospective study [59] demonstrated large adsorption of piperacillin, vancomycin and fluoroquinolones on the resin cartridge, which decreased over time and was not associated with altered antimicrobials’ bloodstream concentration. In contrast, minimal absorption was reported for Ceftriaxone, Cefotaxime and Ceftazidime [59]. Evidence of adsorption of other antimicrobials during CPFA is limited and further investigations are warranted in this field.

7. Hemoperfusion

Several devices have been implemented in clinical practice with the aim to remove specific mediators in sepsis [12,44,60]. Hemoperfusion allows mediator removal via absorption and is influenced by the interaction between the blood and the internal surface of the device, whose chemical characteristics may promote either selective and non-selective removal of mediators.

7.1. Polymyxin B-Immoilized Cartridge (Toraymyxin)

This device consists of a column made by polystyrene fibers and Polymyxin-B, which is a cationic antibiotic binding endotoxin through ionic and hydrophobic forces. Each session lasts for 120 min and a second cycle has been repeated 24 h afterwards in most of the trials in this field [61]. Toraymyxin has been largely used in clinical practice [62,63], and some in vitro studies demonstrated significant Linezolid retention onto the internal surface of the device, while there was no significant removal of other antimicrobials (Meropenem, Imipenem/Cilastatin, Ceftazidime, Ceforozopram, Cefmetazole, Piperacillin, Ciprofloxacin and Vancomycin) [64,65]. In critical care practice, no significant influence on bloodstream concentration was demonstrated for Meropenem [66], although there is no evidence for other antimicrobials, thus warranting further investigation in this field.

7.2. Porous Polystyrene Cartridge (Cytosorb)

This device contains a column made by highly porous polystyrene divinylbenzene copolymer covered with a biocompatible polyvinylpyrrolidone coating and is used for cytokine removal [12,44,60]. Hemoperfusion with Cytosorb may last 24 h and may be applied while RRT is running. A pre-clinical model on pigs [67] showed that Cytosorb significantly reduced the blood concentration of lipophilic antimicrobials in the range of 55 kDa (Fluconazole, Linezolid, Liposomal amphotericin, Posaconazole and Teicoplanin), while other agents were not influenced by this device (β-lactams: meropenem, piperacillin, ceftriaxone, flucloxacillin and cefepime; antifungals: anidulafungin; aminoglycosides: Tobramycin; quinolones: ciprofloxacin; macrolides: clarithromycin; lincosamides: clindamycin; azoles: metronidazole; antiviral: ganciclovir). Moreover, this study [67] observed that antimicrobial clearance was not stable over time, being highest at the beginning of this therapy. Although some studies have been performed to assess the safety and feasibility of Cytosorb in the management of critically ill septic patients [68,69], no research has ever systematically investigated the impact of this device on antimicrobial removal in daily practice, and the evidence available is restricted to case reports and small case series [70]. Recently, Scharf et al. [33] reported significant vancomycin adsorption with Cytosorb in seven critically ill septic patients, whose suboptimal bloodstream concentrations were attenuated by the two-hourly administration of 500 mg of this drug. In this setting, further clinical investigations are necessary to clarify the impact of Cytosorb on antimicrobial removal.

7.3. Microbind Affinity Blood Filter (Seraph 100)

The Seraph 100 Microbind Affinity Blood Filter (ExThera Medical, Martinez, CA, USA) is a sorbent made with polyethylene beads, whose internal surface has been modified to contain end-point attached heparin [71]. Hemoperfusion with Seraph 100 lasts 24 h and may be applied while RRT is running. The Seraph 100 has been recently introduced in critical care practice, and an in vitro study [72] investigated its absorptive properties on 18 antimicrobials (acyclovir, amphothericin B, ceftazidime, cefazolin, clindamycin, daptomycin, fluconazole, fosfomycin, gentamicin, levofloxacin, linezolid, meropenem, moxifloxacin, piperacillin, rifampicin, tazobactam, tobramycin and vancomycin) added to human donor plasma, showing that aminoglycosides were significantly removed during the first pass through the device. However, no clinical studies have addressed the issue of antimicrobial removal associated with the Seraph 100, and further investigation is warranted in this field.

8. Extracorporeal CO2 Removal and Extracorporeal Membrane Oxygenation

ECCO2-R is applied for the management of patients with hypercapnic respiratory failure (e.g., chronic obstructive pulmonary disease or acute respiratory distress syndrome [73,74]). ECMO is applied in patients with cardiopulmonary failure as: veno-venous ECMO, to provide extracorporeal CO2 removal and oxygenation in the context of Acute Respiratory Distress Syndrome (ARDS); veno-arterial ECMO, to provide organ perfusion in the context of acute cardiac dysfunction (e.g., septic cardiomyopathy) [75]. Although no data exist on antimicrobial removal during ECCO2-R, the delivery of ECMO is associated with Vd increase caused by the intravascular administration of priming solutions, fluid resuscitation and blood products that may alter the PK profile of hydrophilic antibiotics [34,35]. Furthermore, ECMO implies no pulsatile blood flow that may decrease the glomerular filtration rate and induce the renin–angiotensin–aldosterone axis activation, thus increasing fluid retention [34]. Moreover, ECMO may cause antimicrobial adsorption into the extracorporeal circuit, which is enhanced via a roller compared to centrifugal pumps [76], lipophilicity and high protein binding of the drugs [34,35].
Gomez et al. [35] reviewed antimicrobial removal in critically ill patients during ECMO. In vitro studies suggested large sequestration into the extracorporeal device of antimicrobials such as meropenem [77], cefazolin [76], teicoplanin [77], gentamicin [34], polymyxin B [77], vancomycin [78], micafungin [77], voriconazole [77], while this phenomenon was not reported for tigecycline [77], ciprofloxacin [79] and caspofungin [77]. In contrast, in vivo studies reported low bloodstream concentration during ECMO of teicoplanin [80] and voriconazole [81], while other antimicrobial concentrations were not significantly influenced by this device [20,82,83,84,85,86,87]. Recently, Shekar et al. investigated antimicrobial exposure in 85 patients who received ECMO, 38 (44.7%) of whom were on RRT. They found a large variation in the PK parameters and antimicrobial concentrations, with only 70 (56.5%) concentration profiles achieving the target exposure range. Poor target attainment was observed for oseltamivir (33.3%), piperacillin (44.4%) and vancomycin (27.3%). Accordingly, PK characteristics were reported highly variable in patients receiving ECMO, leading to low target exposure attainment when standard antimicrobial dosing regimens are used [88].

9. Effective Antimicrobial Dosing Strategies during ECOS

Appropriate dosing regimens are of paramount importance to achieve a therapeutic concentration of antimicrobials and allow microbiological eradication, contrast the emergence multidrug resistant pathogens [89] and prevent drug overdose and toxicity. In the ICU practice, a pharmacokinetic point-prevalence study [3] on standard antimicrobial dosing in 284 critically ill patients who received ß-lactams for infections, showed that 16% of them did not achieve 50% fT>MIC and that these patients were less likely to have a positive clinical outcome (odds ratio [OR], 0.68; p = 0.009). In contrast, positive clinical outcomes were associated with 50% fT>MIC and 100% fT>MIC ratios (OR, 1.02 and 1.56, respectively; p < 0.03) [3]. Moreover, this study reported large variability β-lactams plasma concentration, which was attenuated via a prolonged infusion (either extended infusion ≥2 h or continuous infusion) [3].
For this reason, several strategies for antimicrobial dosing have been implemented in clinical practice [16]:
  • Unit-level interventions: this strategy includes the administration of antimicrobials driven by the PD characteristics of the drug, leading to the administration of time-dependent antimicrobials (β-lactams [90] and Linezolid [91]) via continuous infusion. However, no evidence exists on the implications of this strategy on the stability of antimicrobials bloodstream concentration during ECOS.
  • Nomograms: this strategy accounts for patient-specific characteristics that may influence the PK profile of the drug (e.g., body weight and renal function [92,93]). Although single dosing nomograms have been implemented in clinical practice, they do not account for the concomitant delivery of ECOS.
  • PK/PD-based antimicrobial dosing program: this strategy includes the use of software that performs a PK assessment based on patient-specific characteristics in conjunction with population pharmacokinetic models, via a Bayesian parametric approach and a Monte Carlo simulation [94]. However, this strategy has never been tested in critically ill patients who receive ECOS.
  • Therapeutic Drug Monitoring (TDM): this strategy includes the evaluation of antimicrobial exposure via the assessment of drug concentration at the site of infection (e.g., blood, epithelial lining fluid or cerebrospinal fluid) and implies dose adjustment according to the pathogen susceptibility to the drug (MIC), in order to improve the PK/PD target attainment. In most of the cases, plasma concentration has been used as a surrogate for antimicrobial exposure at the source of infection [17]. TDM may play a role of paramount importance in the dose adjustment of antimicrobials with intra- and/or inter-individual PK variability and narrow therapeutic index [17], especially when PK characteristics are unknown or difficult to predict due to the patient’s clinical severity and instability. Accordingly, recently published guidelines recommended the TDM use for dose titration of ß-lactams, aminoglycosides, linezolid, teicoplanin, vancomycin and voriconazole [17]. In critically ill patients who receive RRT and ECMO [95,96,97], TDM has been largely used for adjusting the dose of ß-lactams, aminoglycosides, linezolid, teicoplanin, glycopeptides and colistin [17]. Furthermore, some evidence has been reported for daptomycin, fluoroquinolones and Tigecycline [17], although it warrants further investigation.
Currently, TDM has not been widely used in daily clinical practice and significant variation among hospitals was reported in terms of use, antimicrobial selection, sampling time points, assays, PK/PD targets and dose adjustment algorithms [98,99]. Moreover, critically ill septic patients receiving ECOS represent a subpopulation of patients that is commonly excluded from clinical investigations [51]. However, this tool may enable real-time antimicrobial PK measurements at the bedside, thus allowing clinicians to adjust the antimicrobial dose to the evolving patient’s clinical condition and pathogen susceptibility. The use of chromatography-based TDM should be fostered in daily large-scale clinical practice to provide a rapid and reliable detection of antimicrobial concentrations in plasma and tissues (e.g., alveola lining fluid), in order to guide antimicrobial dose titration aiming to improve clinical and microbiological outcomes, even in remote and resource-limited settings [17].

10. Conclusions

In critically ill septic patients who receive ECOS, antimicrobial exposure is highly-variable and may lead to poor target attainment with consequently worse clinical outcomes. In comparison with “standard” dosing regimens, several strategies have been proposed to improve antimicrobial exposure, although low evidence supports their use in daily clinical practice. Among them, the therapeutic drug monitoring appears as a promising tool to efficiently measure the antimicrobial PK and adapt antimicrobial dosing to pathogen susceptibility, in order to target an adequate exposure via a precision medicine and personalized approach. For this reason, further large-scale investigation is necessary to place a role for therapeutic drug monitoring in the management of critically ill septic patients receiving ECOS in daily clinical practice.

Author Contributions

Conceptualization, S.L.C. and M.A.; methodology, S.L.C. and G.D.P.; investigation, S.L.C.; data curation, S.L.C., L.C., P.L., E.S.T., G.P. and D.L.G.; writing—original draft preparation, S.L.C.; writing—review and editing, S.L.C., G.D.P. and M.A.; supervision, G.D.P. and M.A.; project administration, S.L.C. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Singer, M.; Deutschman, C.; Seymour, C.; Shankar-Hari, M.; Annane, D.; Bauer, M.; Bellomo, R.; Bernard, G.; Chiche, J.; Coopersmith, C.; et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016, 315, 801–810. [Google Scholar] [CrossRef] [PubMed]
  2. Rudd, K.; Johnson, S.; Agesa, K.; Shackelford, K.; Tsoi, D.; Kievlan, D.; Colombara, D.; Ikuta, K.; Kissoon, N.; Finfer, S.; et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: Analysis for the global burden of disease study. Lancet 2020, 395, 200–211. [Google Scholar] [CrossRef] [PubMed]
  3. Roberts, J.; Paul, S.; Akova, M.; Bassetti, M.; Waele, J.D.; Dimopoulos, G.; Kaukonen, K.; Koulenti, D.; Martin, C.; Montravers, P.; et al. Dali: Defining antibiotic levels in intensive care unit patients: Are current β-lactam antibiotic doses sufficient for critically ill patients? Clin. Infect. Dis. 2014, 58, 1072–1083. [Google Scholar] [CrossRef] [PubMed]
  4. Seymour, C.; Gesten, F.; Prescott, H.; Friedrich, M.; Iwashyna, T.; Phillips, G.; Lemeshow, S.; Osborn, T.; Terry, K.; Levy, M. Time to treatment and mortality during mandated emergency care for sepsis. N. Engl. J. Med. 2017, 376, 2235–2244. [Google Scholar] [CrossRef]
  5. Pascale, G.D.; Antonelli, M.; Deschepper, M.; Arvaniti, K.; Blot, K.; Brown, B.; Lange, D.d.; De Waele, J.; Dikmen, Y.; Dimopoulos, G.; et al. Poor timing and failure of source control are risk factors for mortality in critically ill patients with secondary peritonitis. Intensive Care Med. 2022, 48, 1593–1606. [Google Scholar] [CrossRef]
  6. Udy, A.; Roberts, J.; Boots, R.; Paterson, D.; Lipman, J. Augmented renal clearance: Implications for antibacterial dosing in the critically ill. Clin. Pharmacokinet. 2010, 49, 1–16. [Google Scholar] [CrossRef]
  7. Jamal, J.; Economou, C.; Lipman, J.; Roberts, J. Improving antibiotic dosing in special situations in the icu: Burns, renal replacement therapy and extracorporeal membrane oxygenation. Curr. Opin. Crit. Care 2012, 18, 460–471. [Google Scholar] [CrossRef]
  8. Ranieri, V.; Brodie, D.; Vincent, J. Extracorporeal organ support: From technological tool to clinical strategy supporting severe organ failure. JAMA 2017, 318, 1105–1106. [Google Scholar] [CrossRef]
  9. Husain-Syed, F.; Ricci, Z.; Brodie, D.; Vincent, J.; Ranieri, V.; Slutsky, A.; Taccone, F.; Gattinoni, L.; Ronco, C. Extracorporeal organ support (ecos) in critical illness and acute kidney injury: From native to artificial organ crosstalk. Intensive Care Med. 2018, 44, 1447–1459. [Google Scholar] [CrossRef]
  10. Villa, G.; Neri, M.; Bellomo, R.; Cerda, J.; De Gaudio, A.; De Rosa, S.; Garzotto, F.; Honore, P.; Kellum, J.; Lorenzin, A.; et al. Nomenclature for renal replacement therapy and blood purification techniques in critically ill patients: Practical applications. Crit. Care 2016, 20, 283. [Google Scholar] [CrossRef]
  11. Neri, M.; Villa, G.; Garzotto, F.; Bagshaw, S.; Bellomo, R.; Cerda, J.; Ferrari, F.; Guggia, S.; Joannidis, M.; Kellum, J.; et al. Nomenclature for renal replacement therapy in acute kidney injury: Basic principles. Crit. Care 2016, 20, 318. [Google Scholar] [CrossRef]
  12. Cutuli, S.; Carelli, S.; Grieco, D.; De Pascale, G. Immune modulation in critically ill septic patients. Medicina 2021, 57, 552. [Google Scholar] [CrossRef] [PubMed]
  13. Tängdén, T.; Martín, V.R.; Felton, T.; Nielsen, E.; Marchand, S.; Brüggemann, R.; Bulitta, J.; Bassetti, M.; Theuretzbacher, U.; Tsuji, B.; et al. The role of infection models and pk/pd modelling for optimising care of critically ill patients with severe infections. Intensive Care Med. 2017, 43, 1021–1032. [Google Scholar] [CrossRef] [PubMed]
  14. Udy, A.; Roberts, J.; Lipman, J. Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Med. 2013, 39, 2070–2082. [Google Scholar] [CrossRef] [PubMed]
  15. Evans, L.; Rhodes, A.; Alhazzani, W.; Antonelli, M.; Coopersmith, C.; French, C.; Machado, F.; Mcintyre, L.; Ostermann, M.; Prescott, H.; et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021, 47, 1181–1247. [Google Scholar] [CrossRef] [PubMed]
  16. Roberts, J.; Roger, C.; De Waele, J. Personalized antibiotic dosing for the critically ill. Intensive Care Med. 2019, 45, 715–718. [Google Scholar] [CrossRef]
  17. Abdul-Aziz, M.; Alffenaar, J.; Bassetti, M.; Bracht, H.; Dimopoulos, G.; Marriott, D.; Neely, M.; Paiva, J.; Pea, F.; Sjovall, F.; et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: A position paper. Intensive Care Med. 2020, 46, 1127–1153. [Google Scholar] [CrossRef]
  18. Dulhunty, J.; Paterson, D.; Webb, S.; Lipman, J. Antimicrobial utilisation in 37 australian and new zealand intensive care units. Anaesth. Intensive Care 2011, 39, 231–237. [Google Scholar] [CrossRef]
  19. Vincent, J.; Sakr, Y.; Singer, M.; Martin-Loeches, I.; Machado, F.; Marshall, J.; Finfer, S.; Pelosi, P.; Brazzi, L.; Aditianingsih, D.; et al. Prevalence and outcomes of infection among patients in intensive care units in 2017. JAMA 2020, 323, 1478–1487. [Google Scholar] [CrossRef]
  20. Cotta, M.; Roberts, J.; Lipman, J. Antibiotic dose optimization in critically ill patients. Med. Intensiva 2015, 39, 563–572. [Google Scholar] [CrossRef]
  21. Charlton, M.; Thompson, J. Pharmacokinetics in sepsis. BJA Educ. 2019, 19, 7–13. [Google Scholar] [CrossRef] [PubMed]
  22. Roberts, J.; Taccone, F.; Lipman, J. Understanding pk/pd. Intensive Care Med. 2016, 42, 1797–1800. [Google Scholar] [CrossRef] [PubMed]
  23. Mouton, J.; Muller, A.; Canton, R.; Giske, C.; Kahlmeter, G.; Turnidge, J. Mic-based dose adjustment: Facts and fables. J. Antimicrob. Chemother. 2018, 73, 564–568. [Google Scholar] [CrossRef] [PubMed]
  24. European Committee on Antimicrobrial Susceptibility Testing (EUCAST). Clinical Breakpoints and Dosing of Antibiotics 2023. Available online: https://www.eucast.org/ (accessed on 4 January 2023).
  25. Mouton, J.; Muller, A.; Canton, R.; Giske, C.; Kahlmeter, G.; Turnidge, J. Mic-based dose adjustment: Facts and fables-authors’ response. J. Antimicrob. Chemother. 2018, 73, 2585–2586. [Google Scholar] [CrossRef]
  26. Pistolesi, V.; Morabito, S.; Di Mario, F.; Regolisti, G.; Cantarelli, C.; Fiaccadori, E. A guide to understanding antimicrobial drug dosing in critically ill patients on renal replacement therapy. Antimicrob. Agents Chemother. 2019, 63, e00583-19. [Google Scholar] [CrossRef]
  27. Vincent, J.; Russell, J.; Jacob, M.; Martin, G.; Guidet, B.; Wernerman, J.; Ferrer, R.; McCluskey, S.; Gattinoni, L. Albumin administration in the acutely ill: What is new and where next? Crit. Care 2014, 18, 231. [Google Scholar] [CrossRef]
  28. Uchino, S.; Kellum, J.; Bellomo, R.; Doig, G.; Morimatsu, H.; Morgera, S.; Schetz, M.; Tan, I.; Bouman, C.; Macedo, E.; et al. Acute renal failure in critically ill patients: A multinational, multicenter study. JAMA 2005, 294, 813–818. [Google Scholar] [CrossRef]
  29. Hoff, B.; Maker, J.; Dager, W.; Heintz, B. Antibiotic dosing for critically ill adult patients receiving intermittent hemodialysis, prolonged intermittent renal replacement therapy, and continuous renal replacement therapy: An update. Ann. Pharmacother. 2020, 54, 43–55. [Google Scholar] [CrossRef]
  30. Thompson, A.; Li, F.; Gross, A. Considerations for medication management and anticoagulation during continuous renal replacement therapy. AACN Adv. Crit. Care 2017, 28, 51–63. [Google Scholar] [CrossRef]
  31. Bauer, P.; Ostermann, M.; Russell, L.; Robba, C.; David, S.; Ferreyro, B.; Castro, J.; Juffermans, N.; Montini, L.; Pirani, T.; et al. Plasma exchange in the intensive care unit: A narrative review. Intensive Care Med. 2022, 48, 1382–1396. [Google Scholar] [CrossRef]
  32. Mariano, F.; Leporati, M.; Carignano, P.; Stella, M.; Vincenti, M.; Biancone, L. Efficient removal of colistin a and b in critically ill patients undergoing cvvhdf and sorbent technologies. J. Nephrol. 2015, 28, 623–631. [Google Scholar] [CrossRef] [PubMed]
  33. Scharf, C.; Weinelt, F.; Schroeder, I.; Paal, M.; Weigand, M.; Zoller, M.; Irlbeck, M.; Kloft, C.; Briegel, J.; Liebchen, U. Does the cytokine adsorber cytosorb® reduce vancomycin exposure in critically ill patients with sepsis or septic shock? A prospective observational study. Ann. Intensive Care 2022, 12, 44. [Google Scholar] [CrossRef] [PubMed]
  34. Shekar, K.; Fraser, J.; Smith, M.; Roberts, J. Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J. Crit. Care 2012, 27, 741. [Google Scholar] [CrossRef] [PubMed]
  35. Gomez, F.; Veita, J.; Laudanski, K. Antibiotics and ecmo in the adult population-persistent challenges and practical guides. Antibiotics 2022, 11, 338. [Google Scholar] [CrossRef] [PubMed]
  36. Choi, G.; Gomersall, C.; Tian, Q.; Joynt, G.; Freebairn, R.; Lipman, J. Principles of antibacterial dosing in continuous renal replacement therapy. Crit. Care Med. 2009, 37, 2268–2282. [Google Scholar] [CrossRef]
  37. Wilson, R.; Soullier, G. The validity of two-hour creatinine clearance studies in critically ill patients. Crit. Care Med. 1980, 8, 281–284. [Google Scholar] [CrossRef]
  38. Hoste, E.J.; Kellum, J.; Selby, N.; Zarbock, A.; Palevsky, P.; Bagshaw, S.; Goldstein, S.; Cerdá, J.; Chawla, L. Global epidemiology and outcomes of acute kidney injury. Nat. Rev. Nephrol. 2018, 14, 607–625. [Google Scholar] [CrossRef]
  39. Bagshaw, S.; Uchino, S.; Bellomo, R.; Morimatsu, H.; Morgera, S.; Schetz, M.; Tan, I.; Bouman, C.; Macedo, E.; Gibney, N.; et al. Septic acute kidney injury in critically ill patients: Clinical characteristics and outcomes. Clin. J. Am. Soc. Nephrol. 2007, 2, 431–439. [Google Scholar] [CrossRef]
  40. Roberts, J.; Joynt, G.; Lee, A.; Choi, G.; Bellomo, R.; Kanji, S.; Mudaliar, M.Y.; Peake, S.; Stephens, D.; Taccone, F.; et al. The effect of renal replacement therapy and antibiotic dose on antibiotic concentrations in critically ill patients: Data from the multinational sampling antibiotics in renal replacement therapy study. Clin. Infect. Dis. 2021, 72, 1369–1378. [Google Scholar] [CrossRef]
  41. Legrand, M.; Darmon, M.; Joannidis, M.; Payen, D. Management of renal replacement therapy in icu patients: An international survey. Intensive Care Med. 2013, 39, 101–108. [Google Scholar] [CrossRef]
  42. Onichimowski, D.; Ziółkowski, H.; Nosek, K.; Jaroszewski, J.; Rypulak, E.; Czuczwar, M. Comparison of adsorption of selected antibiotics on the filters in continuous renal replacement therapy circuits: In vitro studies. J. Artif. Organs 2020, 23, 163–170. [Google Scholar] [CrossRef] [PubMed]
  43. Ulldemolins, M.; Martín-Loeches, I.; Llauradó-Serra, M.; Fernández, J.; Vaquer, S.; Rodríguez, A.; Pontes, C.; Calvo, G.; Torres, A.; Soy, D. Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: Effect of type of dialysis membrane on dosing requirements. J. Antimicrob. Chemother. 2016, 71, 1651–1659. [Google Scholar] [CrossRef] [PubMed]
  44. Cutuli, S.; Grieco, D.; De Pascale, G.; Antonelli, M. Hemadsorption. Curr. Opin. Anaesthesiol. 2021, 34, 113–118. [Google Scholar] [CrossRef]
  45. Wong, W.; Choi, G.; Gomersall, C.; Lipman, J. To increase or decrease dosage of antimicrobials in septic patients during continuous renal replacement therapy: The eternal doubt. Curr. Opin. Pharmacol. 2015, 24, 68–78. [Google Scholar] [CrossRef] [PubMed]
  46. Pinder, M.; Bellomo, R.; Lipman, J. Pharmacological principles of antibiotic prescription in the critically ill. Anaesth. Intensive Care 2002, 30, 134–144. [Google Scholar] [CrossRef]
  47. Roberts, D.; Roberts, J.; Roberts, M.; Liu, X.; Nair, P.; Cole, L.; Lipman, J.; Bellomo, R.; Investigators, R.R.T.S. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: A multicentre pharmacokinetic study. Crit. Care Med. 2012, 40, 1523–1528. [Google Scholar] [CrossRef]
  48. Jamal, J.; Udy, A.; Lipman, J.; Roberts, J. The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: An analysis of published literature and dosing regimens. Crit. Care Med. 2014, 42, 1640–1650. [Google Scholar] [CrossRef]
  49. Roberts, D.; Liu, X.; Roberts, J.; Nair, P.; Cole, L.; Roberts, M.; Lipman, J.; Bellomo, R.; Investigators, R.R.T.S. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Crit. Care 2015, 19, 84. [Google Scholar] [CrossRef]
  50. Joannes-Boyau, O.; Honoré, P.; Perez, P.; Bagshaw, S.; Grand, H.; Canivet, J.; Dewitte, A.; Flamens, C.; Pujol, W.; Grandoulier, A.; et al. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (ivoire study): A multicentre randomized controlled trial. Intensive Care Med. 2013, 39, 1535–1546. [Google Scholar] [CrossRef]
  51. Bakdach, D.; Elajez, R.; Bakdach, A.; Awaisu, A.; De Pascale, G.; Hssain, A. Pharmacokinetics, pharmacodynamics, and dosing considerations of novel β-lactams and β-lactam/β-lactamase inhibitors in critically ill adult patients: Focus on obesity, augmented renal clearance, renal replacement therapies, and extracorporeal membrane oxygenation. J. Clin. Med. 2022, 11, 6898. [Google Scholar]
  52. KDIGO AKI Work Group. Kdigo clinical practice guideline for acute kidney injury. Kidney Int. Suppl. 2012, 17, 1–138. [Google Scholar]
  53. Vicka, V.; Vickiene, A.; Tutkus, J.; Stanaitis, J.; Bandzeviciute, R.; Ringaitiene, D.; Vosylius, S.; Sipylaite, J. Immediate aspiration of the drug infused via central venous catheter through the distally positioned central venous dialysis catheter: An experimental study. J. Vasc. Access 2021, 22, 94–100. [Google Scholar] [CrossRef] [PubMed]
  54. Kam, K.; Mari, J.; Wigmore, T. Adjacent central venous catheters can result in immediate aspiration of infused drugs during renal replacement therapy. Anaesthesia 2012, 67, 115–121. [Google Scholar] [CrossRef] [PubMed]
  55. Frithiof, R.; Bandert, A.; Larsson, A.; Lipcsey, M.; Smekal, D. Central venous line and dialysis catheter position affects drug clearance during continuous renal replacement therapy in an animal model. ASAIO J. 2019, 65, 408–413. [Google Scholar] [CrossRef]
  56. Knaup, H.; Stahl, K.; Schmidt, B.; Idowu, T.; Busch, M.; Wiesner, O.; Welte, T.; Haller, H.; Kielstein, J.; Hoeper, M.; et al. Early therapeutic plasma exchange in septic shock: A prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers. Crit. Care 2018, 22, 285. [Google Scholar] [CrossRef]
  57. Stahl, K.; Schmidt, J.; Seeliger, B.; Schmidt, B.; Welte, T.; Haller, H.; Hoeper, M.; Budde, U.; Bode, C.; David, S. Effect of therapeutic plasma exchange on endothelial activation and coagulation-related parameters in septic shock. Crit. Care 2020, 24, 71. [Google Scholar] [CrossRef]
  58. Krzych, Ł.; Czok, M.; Putowski, Z. Is antimicrobial treatment effective during therapeutic plasma exchange? Investigating the role of possible interactions. Pharmaceutics 2020, 12, 395. [Google Scholar] [CrossRef]
  59. Page, M.; Cohen, S.; Ber, C.; Allaouchiche, B.; Kellum, J.; Rimmelé, T. In vivo antibiotic removal during coupled plasma filtration adsorption: A retrospective study. ASAIO J. 2014, 60, 70–75. [Google Scholar] [CrossRef]
  60. Ricci, Z.; Romagnoli, S.; Reis, T.; Bellomo, R.; Ronco, C. Hemoperfusion in the intensive care unit. Intensive Care Med. 2022, 48, 1397–1408. [Google Scholar] [CrossRef]
  61. Fujii, T.; Ganeko, R.; Kataoka, Y.; Furukawa, T.; Featherstone, R.; Doi, K.; Vincent, J.; Pasero, D.; Robert, R.; Ronco, C.; et al. Polymyxin b-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: A systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2018, 44, 167–178. [Google Scholar] [CrossRef]
  62. Early Use of Polymyxin B Hemoperfusion in the Abdominal Sepsis 2 Collaborative Group. Polymyxin b hemoperfusion in clinical practice: The picture from an unbound collaborative registry. Blood Purif. 2014, 37, 22–25. [Google Scholar] [CrossRef] [PubMed]
  63. Cutuli, S.; Artigas, A.; Fumagalli, R.; Monti, G.; Ranieri, V.; Ronco, C.; Antonelli, M.; EUPHAS 2 Collaborative Group. Polymyxin-B hemoperfusion in septic patients: Analysis of a multicenter registry. Ann. Intensive Care 2016, 6, 77. [Google Scholar] [CrossRef] [PubMed]
  64. Shimokawa, K.; Takakuwa, R.; Taya, K.; Wada, Y.; Yamazaki, N.; Murata, M.; Hirata, K.; Masuno, T.; Yokota, H.; Ishii, F. Adsorption of various antimicrobial agents to endotoxin removal polymyxin-b immobilized fiber (toraymyxin®). Colloids Surf. B Biointerfaces 2012, 90, 58–61. [Google Scholar] [CrossRef] [PubMed]
  65. Shimokawa, K.; Takakuwa, R.; Wada, Y.; Yamazaki, N.; Ishii, F. Adsorption of various antimicrobial agents to endotoxin removal polymyxin-b immobilized fiber (toraymyxin®). Part 2: Adsorption of two drugs to toraymyxin pmx-20r cartridges. Colloids Surf. B Biointerfaces 2013, 101, 350–352. [Google Scholar] [CrossRef]
  66. Singhan, W.; Vadcharavivad, S.; Areepium, N.; Wittayalertpanya, S.; Chaijamorn, W.; Srisawat, N. The effect of direct hemoperfusion with polymyxin b immobilized cartridge on meropenem in critically ill patients requiring renal support. J. Crit. Care 2019, 51, 71–76. [Google Scholar] [CrossRef]
  67. Schneider, A.; André, P.; Scheier, J.; Schmidt, M.; Ziervogel, H.; Buclin, T.; Kindgen-Milles, D. Pharmacokinetics of anti-infective agents during cytosorb hemoadsorption. Sci. Rep. 2021, 11, 10493. [Google Scholar] [CrossRef] [PubMed]
  68. Schädler, D.; Pausch, C.; Heise, D.; Meier-Hellmann, A.; Brederlau, J.; Weiler, N.; Marx, G.; Putensen, C.; Spies, C.; Jörres, A.; et al. The effect of a novel extracorporeal cytokine hemoadsorption device on il-6 elimination in septic patients: A randomized controlled trial. PLoS ONE 2017, 12, e0187015. [Google Scholar] [CrossRef]
  69. Paul, R.; Sathe, P.; Kumar, S.; Prasad, S.; Aleem, M.; Sakhalvalkar, P. Multicentered prospective investigator initiated study to evaluate the clinical outcomes with extracorporeal cytokine adsorption device (cytosorb®) in patients with sepsis and septic shock. World J. Crit. Care Med. 2021, 10, 22–34. [Google Scholar] [CrossRef]
  70. Berlot, G.; Bella, S.D.; Tomasini, A.; Roman-Pognuz, E. The effects of hemoadsorption on the kinetics of antibacterial and antifungal agents. Antibiotics 2022, 11, 180. [Google Scholar] [CrossRef]
  71. Seffer, M.; Cottam, D.; Forni, L.; Kielstein, J. Heparin 2.0: A new approach to the infection crisis. Blood Purif. 2021, 50, 28–34. [Google Scholar] [CrossRef]
  72. Schmidt, J.; Eden, G.; Seffer, M.; Winkler, M.; Kielstein, J. In vitro elimination of anti-infective drugs by the seraph® 100 microbind® affinity blood filter. Clin. Kidney J. 2020, 13, 421–424. [Google Scholar] [CrossRef] [PubMed]
  73. Combes, A.; Auzinger, G.; Capellier, G.; Du Cheyron, D.; Clement, I.; Consales, G.; Dabrowski, W.; De Bels, D.; Ortiz, F.d.M.; Gottschalk, A.; et al. ECCO2R therapy in the icu: Consensus of a european round table meeting. Crit. Care 2020, 24, 490. [Google Scholar] [CrossRef] [PubMed]
  74. Gattinoni, L.; Coppola, S.; Camporota, L. Physiology of extracorporeal CO2 removal. Intensive Care Med. 2022, 48, 1322–1325. [Google Scholar] [CrossRef] [PubMed]
  75. Mosier, J.; Kelsey, M.; Raz, Y.; Gunnerson, K.; Meyer, R.; Hypes, C.; Malo, J.; Whitmore, S.; Spaite, D. Extracorporeal membrane oxygenation (ecmo) for critically ill adults in the emergency department: History, current applications, and future directions. Crit. Care 2015, 19, 431. [Google Scholar] [CrossRef]
  76. Wildschut, E.; Ahsman, M.; Allegaert, K.; Mathot, R.; Tibboel, D. Determinants of drug absorption in different ecmo circuits. Intensive Care Med. 2010, 36, 2109–2116. [Google Scholar] [CrossRef]
  77. Zhang, Y.; Hu, H.; Zhang, Q.; Ou, Q.; Zhou, H.; Sha, T.; Zeng, Z.; Wu, J.; Lu, J.; Chen, Z. Effects of ex vivo extracorporeal membrane oxygenation circuits on sequestration of antimicrobial agents. Front. Med. 2021, 8, 748769. [Google Scholar] [CrossRef]
  78. Raffaeli, G.; Cavallaro, G.; Allegaert, K.; Koch, B.; Mosca, F.; Tibboel, D.; Wildschut, E. Sequestration of voriconazole and vancomycin into contemporary extracorporeal membrane oxygenation circuits: An in vitro study. Front. Pediatr. 2020, 8, 468. [Google Scholar] [CrossRef]
  79. Cheng, V.; Abdul-Aziz, M.; Roberts, J.; Shekar, K. Optimising drug dosing in patients receiving extracorporeal membrane oxygenation. J. Thorac. Dis. 2018, 10, S629–S641. [Google Scholar] [CrossRef]
  80. Wi, J.; Noh, H.; Min, K.; Yang, S.; Jin, B.; Hahn, J.; Bae, S.; Kim, J.; Park, M.; Choi, D.; et al. Population pharmacokinetics and dose optimization of teicoplanin during venoarterial extracorporeal membrane oxygenation. Antimicrob. Agents Chemother. 2017, 61, e01015–e01017. [Google Scholar] [CrossRef]
  81. Daele, R.V.; Bekkers, B.; Lindfors, M.; Broman, L.; Schauwvlieghe, A.; Rijnders, B.; Hunfeld, N.; Juffermans, N.; Taccone, F.; Sousa, C.; et al. A large retrospective assessment of voriconazole exposure in patients treated with extracorporeal membrane oxygenation. Microorganisms 2021, 9, 1543. [Google Scholar] [CrossRef]
  82. Lee, J.; Lee, D.; Kim, J.; Jung, W.; Heo, W.; Kim, Y.; Kim, S.; No, T.; Jo, K.; Ko, J.; et al. Pharmacokinetics and monte carlo simulation of meropenem in critically ill adult patients receiving extracorporeal membrane oxygenation. Front. Pharmacol. 2021, 12, 2984. [Google Scholar] [CrossRef] [PubMed]
  83. Liu, D.; Chen, W.; Wang, Q.; Li, M.; Zhang, Z.; Cui, G.; Li, P.; Zhang, X.; Ma, Y.; Zhan, Q.; et al. Influence of venovenous extracorporeal membrane oxygenation on pharmacokinetics of vancomycin in lung transplant recipients. J. Clin. Pharm. Ther. 2020, 45, 1066–1075. [Google Scholar] [CrossRef] [PubMed]
  84. Donadello, K.; Roberts, J.; Cristallini, S.; Beumier, M.; Shekar, K.; Jacobs, F.; Belhaj, A.; Vincent, J.; de Backer, D.; Taccone, F. Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy: A matched cohort study. Crit. Care 2014, 18, 632. [Google Scholar] [CrossRef] [PubMed]
  85. Mehta, N.; Halwick, D.; Dodson, B.; Thompson, J.; Arnold, J. Potential drug sequestration during extracorporeal membrane oxygenation: Results from an ex vivo experiment. Intensive Care Med. 2007, 33, 1018–1024. [Google Scholar] [CrossRef] [PubMed]
  86. Shekar, K.; Roberts, J.; Mcdonald, C.; Fisquet, S.; Barnett, A.; Mullany, D.; Ghassabian, S.; Wallis, S.; Fung, Y.; Smith, M.; et al. Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. Crit. Care 2012, 16, R194. [Google Scholar] [CrossRef] [PubMed]
  87. Spriet, I.; Annaert, P.; Meersseman, P.; Hermans, G.; Meersseman, W.; Verbesselt, R.; Willems, L. Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation. J. Antimicrob. Chemother. 2009, 63, 767–770. [Google Scholar] [CrossRef]
  88. Shekar, K.; Abdul-Aziz, M.; Cheng, V.; Burrows, F.; Buscher, H.; Cho, Y.; Corley, A.; Diehl, A.; Gilder, E.; Jakob, S.; et al. Antimicrobial exposures in critically ill patients receiving extracorporeal membrane oxygenation. Am. J. Respir. Crit. Care Med. 2022. Online ahead of print. [Google Scholar] [CrossRef]
  89. Roberts, J.; Kruger, P.; Paterson, D.; Lipman, J. Antibiotic resistance—What’s dosing got to do with it? Crit. Care Med. 2008, 36, 2433–2440. [Google Scholar] [CrossRef]
  90. Dulhunty, J.; Roberts, J.; Davis, J.; Webb, S.; Bellomo, R.; Gomersall, C.; Shirwadkar, C.; Eastwood, G.; Myburgh, J.; Paterson, D.; et al. A multicenter randomized trial of continuous versus intermittent β-lactam infusion in severe sepsis. Am. J. Respir. Crit. Care Med. 2015, 192, 1298–1305. [Google Scholar] [CrossRef]
  91. De Pascale, G.; Fortuna, S.; Tumbarello, M.; Cutuli, S.; Vallecoccia, M.; Spanu, T.; Bello, G.; Montini, L.; Pennisi, M.; Navarra, P.; et al. Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: Intermittent vs continuous administration. Intensive Care Med. 2015, 41, 103–110. [Google Scholar] [CrossRef]
  92. Pea, F.; Viale, P.; Cojutti, P.; Furlanut, M. Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: A pharmacokinetics/pharmacodynamics-based approach. Antimicrob. Agents Chemother. 2012, 56, 6343–6348. [Google Scholar] [CrossRef] [PubMed]
  93. Cristallini, S.; Hites, M.; Kabtouri, H.; Roberts, J.; Beumier, M.; Cotton, F.; Lipman, J.; Jacobs, F.; Vincent, J.; Creteur, J.; et al. New regimen for continuous infusion of vancomycin in critically ill patients. Antimicrob. Agents Chemother. 2016, 60, 4750–4756. [Google Scholar] [CrossRef] [PubMed]
  94. Heil, E.; Nicolau, D.; Farkas, A.; Roberts, J.; Thom, K. Pharmacodynamic target attainment for cefepime, meropenem, and piperacillin-tazobactam using a pharmacokinetic/pharmacodynamic-based dosing calculator in critically ill patients. Antimicrob. Agents Chemother. 2018, 62, e01008–e01018. [Google Scholar] [CrossRef] [PubMed]
  95. Bouglé, A.; Dujardin, O.; Lepère, V.; Hamou, N.; Vidal, C.; Lebreton, G.; Salem, J.; El-Helali, N.; Petijean, G.; Amour, J. Pharmecmo: Therapeutic drug monitoring and adequacy of current dosing regimens of antibiotics in patients on extracorporeal life support. Anaesth. Crit. Care Pain Med. 2019, 38, 493–497. [Google Scholar] [CrossRef] [PubMed]
  96. Kühn, D.; Metz, C.; Seiler, F.; Wehrfritz, H.; Roth, S.; Alqudrah, M.; Becker, A.; Bracht, H.; Wagenpfeil, S.; Hoffmann, M.; et al. Antibiotic therapeutic drug monitoring in intensive care patients treated with different modalities of extracorporeal membrane oxygenation (ecmo) and renal replacement therapy: A prospective, observational single-center study. Crit. Care 2020, 24, 664. [Google Scholar] [CrossRef]
  97. Matusik, E.; Boidin, C.; Friggeri, A.; Richard, J.; Bitker, L.; Roberts, J.; Goutelle, S. Therapeutic drug monitoring of antibiotic drugs in patients receiving continuous renal replacement therapy or intermittent hemodialysis: A critical review. Ther. Drug Monit. 2022, 44, 86–102. [Google Scholar] [CrossRef]
  98. Tabah, A.; Waele, J.D.; Lipman, J.; Zahar, J.; Cotta, M.; Barton, G.; Timsit, J.; Roberts, J.; Working Group for Antimicrobial Use in the ICU within the Infection Section of the European Society of Intensive Care Medicine (ESICM). The ADMIN-ICU survey: A survey on antimicrobial dosing and monitoring in icus. J. Antimicrob. Chemother. 2015, 70, 2671–2677. [Google Scholar] [CrossRef]
  99. Wong, G.; Brinkman, A.; Benefield, R.; Carlier, M.; De Waele, J.; Helali, N.E.; Frey, O.; Harbarth, S.; Huttner, A.; McWhinney, B.; et al. An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J. Antimicrob. Chemother. 2014, 69, 1416–1423. [Google Scholar] [CrossRef]
Microorganisms 11 00473 g001 550
Figure 1. PK/PD indexes. Abbreviations: AUC, area under curve; MIC, minimum inhibitory concentration; PD, pharmacodynamic; PK, pharmacokinetic.
Figure 1. PK/PD indexes. Abbreviations: AUC, area under curve; MIC, minimum inhibitory concentration; PD, pharmacodynamic; PK, pharmacokinetic.
Microorganisms 11 00473 g001
Table
Table 1. PK/PD characteristics of antimicrobials.
Table 1. PK/PD characteristics of antimicrobials.
AntimicrobialsPK/PD IndexFree Fraction%Volume of Distribution (L kg−1)Route of Elimination
ANTIBIOTICS
β-lactams
Amoxicillin/clavulanatefT>MIC82/750.36/0.21R/L
Piperacillin/TazobactamfT>MIC70/780.24/0.40R
OxacillinfT>MIC6–100.4R
CeftriaxonefT>MIC100.1–0.2R/L
CefepimefT>MIC840.3R
CeftarolinefT>MIC800.29R
CeftazidimefT>MIC900.28–0.40R
Ceftazidime/AvibactamfT>MIC90/920.28/0.31R
Ceftolozane/TazobactamfT>MIC80/780.19/0.40R
CefiderocolfT>MIC600.26R
MeropenemfT>MIC980.35R
Imipenem/CilastatinfT>MIC80/560.22–0.24R
Meropenem/VaborbactamfT>MIC98/770.28/0.25R
Aminoglycosides
AmikacinCmax/MIC>950.22–0.5R
GentamicinCmax/MIC>950.36R
Glyco-, glycolipo- and Lipopeptides
DaptomycinAUC24/MIC200.1–0.13R
TeicoplaninAUC24/MIC10–400.5–1.2R
VancomycinAUC24/MIC50–900.47–1.1R
Glycylcycline
TigecyclineAUC24/MIC11–290.12L
Lincosamides
ClindamycinAUC24/MIC5–151.1L
Macrolides
AzithromycinAUC24/MIC50–930.47L
Monobactam
AztreonamfT>MIC440.18R
Nitroimidazoles
MetronidazoleAUC24/MIC800.6–0.85R
Oxazolidinones
LinezolidAUC24/MIC700.5–0.8L
TedizolidAUC24/MIC50–900.95–1.14L
Polymyxins
ColistinAUC24/MIC59–740.3–0.4R
Quinolones
CiprofloxacinAUC24/MIC60–802.5R/L
Levofloxacin AUC24/MIC60–751.1–1.5R
Rifamycins
RifampinAUC24/MIC200.65R/L
Tetracyclines
DoxycyclineAUC24/MIC70.75–1.91R/L
ANTIMYCOTICS
Liposomal Amphotericin BCmax/MIC104R/L
FluconazoleAUC24/MIC880.7R
IsavuconazoleAUC24/MIC<16.42R/L
ItraconazoleAUC24/MIC<10.14L
PosaconazoleAUC24/MIC<13.22–4.21L
VoriconazoleAUC24/MIC404.6L
AnidulafunginAUC24/MIC<10.4–0.7L
CaspofunginAUC24/MIC30.11L
ANTIVIRALS
Acyclovir-91–670.7R
Ganciclovir-99–980.7R
Oseltamivir-9723–26R
Remdesivir-<202.05R
Abbreviations: L, liver; MIC, minimum inhibitory concentration; R, renal; fT>MIC, time of free fraction concentration above MIC (time-dependent antimicrobials); Cmax/MIC, peak of maximum concentration above MIC (concentration dependent antimicrobials); AUC24/MIC, area under the concentration–time curve over 24 h above MIC (concentration-dependent with time dependence antimicrobials).
Table
Table 2. Extracorporeal Organ Support Therapy.
Table 2. Extracorporeal Organ Support Therapy.
Extracorporeal Organ Support TherapyReferences
Extracorporeal Blood Purification TherapiesMicroorganisms 11 00473 i001CRRTContinuous Renal Replacement Therapy (CRRT) allows blood purification from the life-threatening waste product overload occurring during acute kidney injury. The three main mechanisms of solute and fluid removal during CRRT are:
−
continuous venous–venous haemodialysis (CVVHD), trans-membrane solute removal via concentration gradient (diffusion).
−
continuous venous–venous haemofiltration (CVVHF), trans-membrane water and solute removal via pressure gradient (filtration).
−
continuous venous–venous haemodiafiltration (CVVHDF), combines CVVHD and CVVHF.
Antimicrobial PK characteristics that may favour drug removal during CRRT are: hydrophilicity, small molecular weight (<500–1000 Da), low protein binding (<80%) and small Vd (<2 L/Kg).		[29,30]
Microorganisms 11 00473 i002TPETherapeutic plasma exchange (TPE) allows plasma filtration via high cut-off membranes and subsequent replacement with solutions of donor plasma, colloids, crystalloids or a mixture thereof. Main indications for this therapy are represented by immunopathological conditions such as myasthenia gravis, Guillain–Barré syndrome and Waldenström macroglobulinemia. However, TPE has been used in patients with sepsis, although no definitive evidence exists in this field.Antimicrobial PK characteristics that may favour drug removal during TPE are low Vd and high protein binding (>80%).[31]
Microorganisms 11 00473 i003CPFA Coupled plasma filtration and adsorption (CPFA) combines plasma filtration via high cut-off membranes with subsequent adsorption via styrene resin. The volume plasma purified by waste products is then reinfused into the blood line and the whole blood passes across an hemofilter for further solute removal. This therapy has been used in septic patents, although clear benefit has never been demonstrated.CPFA was demonstrated to significantly lower the bloodstream concentration of colistin, whose amount was directly proportional to the volume of plasma filtered over time.[32]
Microorganisms 11 00473 i004HPHemoperfusion allows extracorporeal removal of mediators via absorption and, according to cartridge characteristics, may be classified as:
Selective
⇒
Endotoxin removal via Polymyxin B-immobilized cartridge (Toraymyxin); no evidence of significant antimicrobial removal in vivo.
Non selective
⇒
Cytokine removal via porous polystyrene cartridge (Cytosorb); small case series reported significant absorption of vancomycin.
⇒
Pathogen removal via microbind affinity blood filter (Seraph 100); no evidence of significant antimicrobial removal in vivo.
[33]
Cardio-pulmonary supportMicroorganisms 11 00473 i005ECCO2R Extracorporeal CO2 removal (ECCO2R) allows CO2 removal in hypercapnic respiratory diseases (e.g., COPD and ARDS); no evidence of significant antimicrobial removal in vivo.
Microorganisms 11 00473 i006ECMOExtracorporeal membrane oxygenation (ECMO) may be set as:
⇒
Veno-venous ECMO, that allows blood oxygenation and CO2 removal, and is indicated in patients affected by acute severe gas exchange alterations (e.g., ARDS);
⇒
Veno-arterial ECMO, that allows cardiac output replacement and is indicated in patients with cardiogenic shock.
Antimicrobial PK characteristics that may favour drug removal during ECMO are lipophilicity and high protein binding (>80%).		[34,35]
Abbreviations: ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; CPFA, continuous plasma filtration and absorption; CRRT, continuous renal replacement therapy; ECCO2R, extracorporeal carbon dioxide removal; ECMO, extracorporeal membrane oxygenation; HP, hemoperfusion; PK, pharmacokinetic; TPE, therapeutic plasma exchange; Vd, volume of distribution.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Cutuli, S.L.; Cascarano, L.; Lazzaro, P.; Tanzarella, E.S.; Pintaudi, G.; Grieco, D.L.; De Pascale, G.; Antonelli, M. Antimicrobial Exposure in Critically Ill Patients with Sepsis-Associated Multi-Organ Dysfunction Requiring Extracorporeal Organ Support: A Narrative Review. Microorganisms 2023, 11, 473. https://doi.org/10.3390/microorganisms11020473

AMA Style

Cutuli SL, Cascarano L, Lazzaro P, Tanzarella ES, Pintaudi G, Grieco DL, De Pascale G, Antonelli M. Antimicrobial Exposure in Critically Ill Patients with Sepsis-Associated Multi-Organ Dysfunction Requiring Extracorporeal Organ Support: A Narrative Review. Microorganisms. 2023; 11(2):473. https://doi.org/10.3390/microorganisms11020473

Chicago/Turabian Style

Cutuli, Salvatore Lucio, Laura Cascarano, Paolo Lazzaro, Eloisa Sofia Tanzarella, Gabriele Pintaudi, Domenico Luca Grieco, Gennaro De Pascale, and Massimo Antonelli. 2023. "Antimicrobial Exposure in Critically Ill Patients with Sepsis-Associated Multi-Organ Dysfunction Requiring Extracorporeal Organ Support: A Narrative Review" Microorganisms 11, no. 2: 473. https://doi.org/10.3390/microorganisms11020473

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop